Equities analysts expect Zimmer Biomet (NYSE:ZBH) to report earnings per share (EPS) of $1.88 for the current quarter, Zacks reports. Twelve analysts have made estimates for Zimmer Biomet’s earnings. The lowest EPS estimate is $1.85 and the highest is $1.92. Zimmer Biomet reported earnings of $2.08 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 9.6%. The firm is scheduled to issue its next quarterly earnings report on Thursday, July 26th.
On average, analysts expect that Zimmer Biomet will report full-year earnings of $7.67 per share for the current fiscal year, with EPS estimates ranging from $7.60 to $7.77. For the next fiscal year, analysts forecast that the company will report earnings of $8.02 per share, with EPS estimates ranging from $7.88 to $8.10. Zacks’ EPS calculations are an average based on a survey of research analysts that cover Zimmer Biomet.
Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, April 26th. The medical equipment provider reported $1.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.89 by $0.02. The firm had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $1.98 billion. Zimmer Biomet had a return on equity of 14.36% and a net margin of 21.81%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.13 EPS.
Several analysts have weighed in on ZBH shares. Citigroup dropped their price objective on Zimmer Biomet from $132.00 to $121.00 and set a “neutral” rating for the company in a report on Tuesday, February 27th. ValuEngine cut Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Friday, March 23rd. Morgan Stanley dropped their price objective on Zimmer Biomet from $150.00 to $148.00 and set an “overweight” rating for the company in a report on Monday, February 26th. Robert W. Baird cut Zimmer Biomet from an “outperform” rating to a “neutral” rating in a report on Friday, March 23rd. Finally, Evercore ISI started coverage on Zimmer Biomet in a report on Monday, April 2nd. They set an “in-line” rating and a $115.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $137.71.
In related news, VP Tony W. Collins sold 1,330 shares of the business’s stock in a transaction that occurred on Monday, April 30th. The stock was sold at an average price of $116.73, for a total value of $155,250.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Bryan C. Hanson acquired 25,077 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was acquired at an average price of $119.68 per share, with a total value of $3,001,215.36. The disclosure for this purchase can be found here. 0.71% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of ZBH. Bedel Financial Consulting Inc. acquired a new position in shares of Zimmer Biomet in the 1st quarter valued at approximately $111,000. Massey Quick Simon & CO. LLC grew its position in shares of Zimmer Biomet by 100.0% in the 1st quarter. Massey Quick Simon & CO. LLC now owns 1,200 shares of the medical equipment provider’s stock valued at $131,000 after purchasing an additional 600 shares during the period. Cerebellum GP LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $133,000. We Are One Seven LLC acquired a new position in Zimmer Biomet during the 4th quarter worth approximately $137,000. Finally, Adviser Investments LLC acquired a new position in Zimmer Biomet during the 1st quarter worth approximately $144,000. Institutional investors and hedge funds own 86.45% of the company’s stock.
NYSE:ZBH traded down $0.55 on Monday, hitting $114.50. 1,330,917 shares of the stock were exchanged, compared to its average volume of 1,506,360. The stock has a market capitalization of $23.39 billion, a P/E ratio of 14.26, a P/E/G ratio of 2.25 and a beta of 1.16. Zimmer Biomet has a 52 week low of $104.28 and a 52 week high of $133.49. The company has a current ratio of 1.69, a quick ratio of 1.07 and a debt-to-equity ratio of 0.79.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 30th. Investors of record on Thursday, March 29th were given a $0.24 dividend. The ex-dividend date of this dividend was Wednesday, March 28th. This represents a $0.96 annualized dividend and a dividend yield of 0.84%. Zimmer Biomet’s dividend payout ratio is presently 11.96%.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.